Meyahealth
HomeGeneticsGeneRYR2 gene
Back to Gene
RYR2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

RYR2 gene

The RYR2 gene provides instructions for creating a protein essential for regulating heart rhythm through the controlled release of calcium ions in cardiac muscle cells.

Normal Function

The RYR2 gene provides instructions for making a protein called ryanodine receptor 2. This protein belongs to a family of receptors that form channels responsible for transporting positively charged calcium atoms (calcium ions) within cells.

These channels are located in the heart (cardiac) muscle cells, known as myocytes. They are embedded in the outer membrane of the sarcoplasmic reticulum, a cell structure that stores calcium ions. The RYR2 channel acts as a gatekeeper, controlling the flow of calcium ions out of this storage center.

For the heart to beat normally, cardiac muscle must contract and relax in a coordinated cycle, which is driven by the precise movement of calcium ions:

  • In response to signals, the RYR2 channel releases calcium ions from the sarcoplasmic reticulum into the surrounding cell fluid (the cytoplasm).
  • This increase in calcium concentration triggers the cardiac muscle to contract, pumping blood out of the heart.
  • Calcium ions are then transported back into the sarcoplasmic reticulum, allowing the muscle to relax.

This cycle of release and reuptake produces a regular heart rhythm.

Health Conditions Related to Genetic Changes

Catecholaminergic polymorphic ventricular tachycardia

More than 200 mutations in the RYR2 gene have been linked to catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition causes an abnormal heart rhythm (arrhythmia) during exercise or emotional stress, which can be fatal.

  • Most mutations change single amino acids in the ryanodine receptor 2 protein, altering the channel's structure and function.
  • Research suggests these mutations may interfere with channel regulation or cause the channel to stay open abnormally, leading to a "leak" of calcium ions.
  • These disruptions in calcium flow within myocytes can trigger the irregular heart rhythms characteristic of CPVT.

Arrhythmogenic right ventricular cardiomyopathy

Certain RYR2 gene mutations cause arrhythmogenic right ventricular cardiomyopathy (ARVC). This condition involves the gradual breakdown of heart muscle, increasing the risk of arrhythmia and sudden death. Similar to CPVT, these mutations alter the structure of the RYR2 channel, likely causing a calcium "leak" that disrupts normal heart rhythm.

Familial atrial fibrillation

The RYR2 gene is also associated with familial atrial fibrillation, a condition characterized by irregular, rapid heartbeats originating in the upper chambers of the heart.

Frequently Asked Questions

Yes, RYR2-related CPVT is usually inherited in an autosomal dominant pattern, meaning a child has a 50% chance of inheriting the mutation if one parent is affected. Family members of someone diagnosed with an RYR2 mutation are often recommended for genetic testing and cardiac screening to identify those at risk, even if they show no symptoms.
The primary warning signs of CPVT are episodes of abnormal heart rhythm (arrhythmia) that occur during physical exercise, intense emotional stress, or sudden fright. Symptoms can include palpitations, lightheadedness, fainting (syncope), or in severe cases, sudden cardiac arrest.
The RYR2 gene provides instructions for a protein that forms a calcium channel in heart muscle cells, crucial for regulating heartbeats. Mutations in RYR2 interfere with the precise control of calcium release from storage within these cells. This disruption causes an uncontrolled surge of calcium, leading to irregular and potentially dangerous heart rhythms, especially under stress.
Individuals with RYR2-related CPVT are typically advised to avoid strenuous physical activity, competitive sports, and situations that cause extreme emotional stress or fright, as these can trigger dangerous arrhythmias. Management often includes medication, such as beta-blockers, and sometimes an implantable cardioverter-defibrillator (ICD) for high-risk patients.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ